VistaGen Therapeutics
Biopharmaceutical company developing innovative product candidates for patients with diseases and disorders involving the cns.
Launch date
Employees
Market cap
€78.5m
Enterprise valuation
(€18m) (Public information from Sep 2024)
Share price
$3 VTGN
San Francisco California (HQ)
Financials
Estimates*
USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 1.1m | 1.1m | (<1m) | 1.1m | <1m | <1m | 2.5m |
% growth | - | 2 % | (120 %) | (568 %) | (52 %) | (57 %) | 1032 % |
EBITDA | (17.8m) | (46.8m) | (59.3m) | (32.5m) | - | - | - |
% EBITDA margin | (1634 %) | (4222 %) | 26075 % | (3050 %) | - | - | - |
Profit | (17.9m) | (47.8m) | (59.2m) | (29.4m) | (55.5m) | (77.1m) | (76.3m) |
% profit margin | (1646 %) | (4307 %) | 26066 % | (2760 %) | (10752 %) | (34909 %) | (3053 %) |
EV / revenue | 280.2x | 230.9x | -120.3x | 22.1x | 49.9x | -709.7x | 37.8x |
EV / EBITDA | -17.1x | -5.5x | -0.5x | -0.7x | - | - | - |
R&D budget | 12.5m | 35.4m | 44.4m | 20.0m | - | - | - |
R&D % of revenue | 1145 % | 3193 % | (19524 %) | 1882 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
$3.8m | Early VC | ||
$1.0m | Early VC | ||
N/A | N/A | IPO | |
N/A | $500k | Debt | |
N/A | $36.0m | Post IPO Equity | |
N/A | $1.6m | Early VC | |
N/A | $1.9m | Early VC | |
N/A | $10.0m | Post IPO Equity | |
* | $100m | Post IPO Equity | |
Total Funding | €7.5m |
Recent News about VistaGen Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by VistaGen Therapeutics
EditACQUISITION by VistaGen Therapeutics Dec 2022